vs
Apellis Pharmaceuticals, Inc.（APLS）与CATHAY GENERAL BANCORP（CATY）财务数据对比。点击上方公司名可切换其他公司
CATHAY GENERAL BANCORP的季度营收约是Apellis Pharmaceuticals, Inc.的1.1倍（$222.8M vs $199.9M），CATHAY GENERAL BANCORP净利率更高（653.4% vs -29.5%，领先682.9%），CATHAY GENERAL BANCORP同比增速更快（19.5% vs -5.9%），CATHAY GENERAL BANCORP自由现金流更多（$363.7M vs $-14.3M），过去两年CATHAY GENERAL BANCORP的营收复合增速更高（12.8% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
国泰万通金控是总部位于美国的银行控股公司，旗下运营国泰银行，面向亚裔社区、中小企业提供个人及商业存贷款、财富管理等金融服务，业务覆盖加州、纽约、得州等美国多州及部分亚洲市场。
APLS vs CATY — 直观对比
营收规模更大
CATY
是对方的1.1倍
$199.9M
营收增速更快
CATY
高出25.4%
-5.9%
净利率更高
CATY
高出682.9%
-29.5%
自由现金流更多
CATY
多$377.9M
$-14.3M
两年增速更快
CATY
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $222.8M |
| 净利润 | $-59.0M | $90.5M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 50.9% |
| 净利率 | -29.5% | 653.4% |
| 营收同比 | -5.9% | 19.5% |
| 净利润同比 | -62.2% | 12.9% |
| 每股收益（稀释后） | $-0.40 | $1.33 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSCATY
| Q4 25 | $199.9M | $222.8M | ||
| Q3 25 | $458.6M | $210.6M | ||
| Q2 25 | $178.5M | $196.6M | ||
| Q1 25 | $166.8M | $187.8M | ||
| Q4 24 | $212.5M | $186.5M | ||
| Q3 24 | $196.8M | $189.5M | ||
| Q2 24 | $199.7M | $178.5M | ||
| Q1 24 | $172.3M | $175.2M |
净利润APLSCATY
| Q4 25 | $-59.0M | $90.5M | ||
| Q3 25 | $215.7M | $77.7M | ||
| Q2 25 | $-42.2M | $77.5M | ||
| Q1 25 | $-92.2M | $69.5M | ||
| Q4 24 | $-36.4M | $80.2M | ||
| Q3 24 | $-57.4M | $67.5M | ||
| Q2 24 | $-37.7M | $66.8M | ||
| Q1 24 | $-66.4M | $71.4M |
营业利润率APLSCATY
| Q4 25 | -25.6% | 50.9% | ||
| Q3 25 | 48.7% | 44.5% | ||
| Q2 25 | -18.6% | 49.0% | ||
| Q1 25 | -50.0% | 46.1% | ||
| Q4 24 | -12.3% | 46.5% | ||
| Q3 24 | -24.0% | 41.2% | ||
| Q2 24 | -14.7% | 40.7% | ||
| Q1 24 | -36.0% | 45.7% |
净利率APLSCATY
| Q4 25 | -29.5% | 653.4% | ||
| Q3 25 | 47.0% | 36.9% | ||
| Q2 25 | -23.6% | 39.4% | ||
| Q1 25 | -55.3% | 37.0% | ||
| Q4 24 | -17.1% | 587.9% | ||
| Q3 24 | -29.2% | 35.6% | ||
| Q2 24 | -18.9% | 37.4% | ||
| Q1 24 | -38.5% | 40.8% |
每股收益（稀释后）APLSCATY
| Q4 25 | $-0.40 | $1.33 | ||
| Q3 25 | $1.67 | $1.13 | ||
| Q2 25 | $-0.33 | $1.10 | ||
| Q1 25 | $-0.74 | $0.98 | ||
| Q4 24 | $-0.30 | $1.11 | ||
| Q3 24 | $-0.46 | $0.94 | ||
| Q2 24 | $-0.30 | $0.92 | ||
| Q1 24 | $-0.54 | $0.98 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | — |
| 总债务越低越好 | — | $119.1M |
| 股东权益账面价值 | $370.1M | $2.9B |
| 总资产 | $1.1B | $24.2B |
| 负债/权益比越低杠杆越低 | — | 0.04× |
8季度趋势，按日历期对齐
现金及短期投资APLSCATY
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | — | ||
| Q2 25 | $370.0M | — | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | — | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | $360.1M | — | ||
| Q1 24 | $325.9M | — |
总债务APLSCATY
| Q4 25 | — | $119.1M | ||
| Q3 25 | — | $119.1M | ||
| Q2 25 | — | $119.1M | ||
| Q1 25 | — | $119.1M | ||
| Q4 24 | — | $119.1M | ||
| Q3 24 | — | $119.1M | ||
| Q2 24 | — | $119.1M | ||
| Q1 24 | $93.1M | $119.1M |
股东权益APLSCATY
| Q4 25 | $370.1M | $2.9B | ||
| Q3 25 | $401.2M | $2.9B | ||
| Q2 25 | $156.3M | $2.9B | ||
| Q1 25 | $164.2M | $2.9B | ||
| Q4 24 | $228.5M | $2.8B | ||
| Q3 24 | $237.1M | $2.8B | ||
| Q2 24 | $264.3M | $2.8B | ||
| Q1 24 | $266.7M | $2.8B |
总资产APLSCATY
| Q4 25 | $1.1B | $24.2B | ||
| Q3 25 | $1.1B | $24.1B | ||
| Q2 25 | $821.4M | $23.7B | ||
| Q1 25 | $807.3M | $23.2B | ||
| Q4 24 | $885.1M | $23.1B | ||
| Q3 24 | $901.9M | $23.3B | ||
| Q2 24 | $904.5M | $23.2B | ||
| Q1 24 | $831.9M | $23.4B |
负债/权益比APLSCATY
| Q4 25 | — | 0.04× | ||
| Q3 25 | — | 0.04× | ||
| Q2 25 | — | 0.04× | ||
| Q1 25 | — | 0.04× | ||
| Q4 24 | — | 0.04× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | 0.35× | 0.04× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $368.6M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $363.7M |
| 自由现金流率自由现金流/营收 | -7.1% | 163.2% |
| 资本支出强度资本支出/营收 | 0.1% | 2.2% |
| 现金转化率经营现金流/净利润 | — | 4.07× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $672.7M |
8季度趋势，按日历期对齐
经营现金流APLSCATY
| Q4 25 | $-14.2M | $368.6M | ||
| Q3 25 | $108.5M | $150.6M | ||
| Q2 25 | $4.4M | $64.0M | ||
| Q1 25 | $-53.4M | $99.0M | ||
| Q4 24 | $19.4M | $329.2M | ||
| Q3 24 | $34.1M | $81.2M | ||
| Q2 24 | $-8.3M | $72.9M | ||
| Q1 24 | $-133.0M | $88.2M |
自由现金流APLSCATY
| Q4 25 | $-14.3M | $363.7M | ||
| Q3 25 | $108.3M | $150.1M | ||
| Q2 25 | $4.4M | $62.7M | ||
| Q1 25 | $-53.4M | $96.3M | ||
| Q4 24 | $19.3M | $325.5M | ||
| Q3 24 | — | $80.0M | ||
| Q2 24 | $-8.4M | $72.4M | ||
| Q1 24 | $-133.3M | $87.3M |
自由现金流率APLSCATY
| Q4 25 | -7.1% | 163.2% | ||
| Q3 25 | 23.6% | 71.3% | ||
| Q2 25 | 2.5% | 31.9% | ||
| Q1 25 | -32.0% | 51.2% | ||
| Q4 24 | 9.1% | 174.6% | ||
| Q3 24 | — | 42.2% | ||
| Q2 24 | -4.2% | 40.5% | ||
| Q1 24 | -77.3% | 49.8% |
资本支出强度APLSCATY
| Q4 25 | 0.1% | 2.2% | ||
| Q3 25 | 0.0% | 0.2% | ||
| Q2 25 | 0.0% | 0.6% | ||
| Q1 25 | 0.0% | 1.4% | ||
| Q4 24 | 0.0% | 1.9% | ||
| Q3 24 | 0.0% | 0.6% | ||
| Q2 24 | 0.0% | 0.3% | ||
| Q1 24 | 0.2% | 0.5% |
现金转化率APLSCATY
| Q4 25 | — | 4.07× | ||
| Q3 25 | 0.50× | 1.94× | ||
| Q2 25 | — | 0.83× | ||
| Q1 25 | — | 1.42× | ||
| Q4 24 | — | 4.10× | ||
| Q3 24 | — | 1.20× | ||
| Q2 24 | — | 1.09× | ||
| Q1 24 | — | 1.23× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
CATY
暂无分部数据
